FMX103 1.5%
FX2016-13
Phase 3 small_molecule completed
Quick answer
FMX103 1.5% for Papulopustular Rosacea is a Phase 3 program (small_molecule) at VYNE Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- VYNE Therapeutics
- Indication
- Papulopustular Rosacea
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed